9,700 Shares in Glaukos Corporation $GKOS Acquired by Strs Ohio

Key Points

• Strs Ohio acquired 9,700 shares of Glaukos Corporation valued at approximately $955,000, highlighting significant institutional interest in the medical instruments supplier.
• Analysts hold a mostly positive outlook on Glaukos, with one rating it as a Strong Buy and setting a price target averaging around $124.83.
• Glaukos reported a revenue of $124.12 million for the last quarter, exceeding analysts' expectations and marking a 29.7% increase year-over-year.

Strs Ohio acquired a new stake in Glaukos Corporation (NYSE:GKOS - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 9,700 shares of the medical instruments supplier's stock, valued at approximately $955,000.

Other institutional investors also recently modified their holdings of the company. Focus Partners Wealth acquired a new stake in Glaukos in the 4th quarter valued at $379,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Glaukos by 20.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 162,326 shares of the medical instruments supplier's stock valued at $24,339,000 after buying an additional 27,889 shares in the last quarter. Forum Financial Management LP acquired a new position in shares of Glaukos during the fourth quarter valued at about $211,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Glaukos during the fourth quarter worth about $12,367,000. Finally, California State Teachers Retirement System increased its position in shares of Glaukos by 7.2% during the fourth quarter. California State Teachers Retirement System now owns 50,949 shares of the medical instruments supplier's stock worth $7,639,000 after acquiring an additional 3,409 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Stock Performance

GKOS stock traded up $1.27 during mid-day trading on Monday, hitting $84.74. The company had a trading volume of 594,073 shares, compared to its average volume of 771,963. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The firm has a market cap of $4.86 billion, a PE ratio of -51.36 and a beta of 0.77. Glaukos Corporation has a 12 month low of $77.10 and a 12 month high of $163.71. The stock's fifty day moving average price is $90.99 and its two-hundred day moving average price is $94.36.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. During the same quarter last year, the business posted ($0.52) EPS. Glaukos's quarterly revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. On average, analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Mizuho set a $130.00 price target on Glaukos in a research note on Thursday, July 31st. Wells Fargo & Company lifted their target price on Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. William Blair upgraded Glaukos to a "strong-buy" rating in a report on Thursday, July 31st. Zacks Research cut Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. Finally, UBS Group lifted their price objective on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and a consensus price target of $123.58.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.